Palvella Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 28, 2026, 7:30 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedPalvella Therapeutics Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations, PDUFA Date February 28, 2027
SCHEDULE 13G/AOct. 28, 2026, 3:44 p.m. ETView on SEC.gov
4Oct. 23, 2026, 4:05 p.m. ETView on SEC.gov
4Oct. 14, 2026, 7:14 p.m. ETView on SEC.gov
4Sept. 18, 2026, 4:05 p.m. ETView on SEC.gov
4Sept. 15, 2026, 9:15 p.m. ETView on SEC.gov
4Sept. 4, 2026, 4:05 p.m. ETView on SEC.gov
4Aug. 20, 2026, 4:05 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:33 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:18 p.m. ETView on SEC.gov
SCHEDULE 13GAug. 10, 2026, 2:12 p.m. ETView on SEC.gov
10-QAug. 4, 2026, 7:51 a.m. ETView on SEC.gov
8-KAug. 4, 2026, 7:30 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
SCHEDULE 13GAug. 3, 2026, 10:48 a.m. ETView on SEC.gov
SCHEDULE 13GJuly 29, 2026, 3:19 p.m. ETView on SEC.gov